Stephen Gitelman, MD

Stephen Gitelman is Professor of Pediatrics and Director of the Pediatric Diabetes Program at the University of California at San Francisco (UCSF), and holds the Mary B. Olney MD /KAK Distinguished Professorship in Pediatric Diabetes and Clinical Research. He received his undergraduate training at Princeton University, medical school training at the University of North Carolina, and completed his Pediatric residency and endocrine fellowship training at UCSF, where he has been ever since.   He is a clinical trialist attempting to find safe and effective means to preserve beta cell function in  type 1 diabetes. He is a Clinical Center Director for the NIH sponsored consortia TrialNet; an investigator in the Immune Tolerance Network; and works closely with industry partners. 

He has joined the BT1 SAC in order to help raise awareness and understanding of T1D beyond his usual clinical practice.  He wants to better communicate the exciting evolving efforts in the T1D research world with the larger T1D community.  These advances include the ability to screen and predict risk for T1D; the use of teplizumab to delay progression to clinical disease in those who are at high risk; and efforts to preserve insulin producing beta cells following diagnosis.